Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations

Eugenio A. Debbia, E. Maioli, S. Roveta, A. Marchese

Research output: Contribution to journalArticle

Abstract

Rifaximin, a poorly absorbed rifamycin derivative, exhibited time-dependent bactericidal activity and at concentrations as low as 1/32 of the minimum inhibitory concentration (MIC) caused morphological alterations in both susceptible and resistant bacterial strains. Spontaneous rifaximin-resistant clones appeared with an incidence of 2.6×10-7. The percentage of Escherichia coli cells cured of various plasmids ranged from: 4.5-70% (Flac), 0-18% (pBP507), 7.7-43.8% (plasmid carrying ESBL genes) and 22.4-41.6% (plasmid encoding toxin from ETEC mex264). 8.4-18.2 and 99%. The MIC of ceftazidime was reduced (2-4 dilutions) in the presence of rifaximin (0.5xMIC) in ESBL producing strains. Rifaximin lowered the viability and virulence of the bacteria even though they developed resistance to the compound. In conclusion, the present findings add new features to the microbiological characteristics of rifaximin and suggest that if in vivo pathogens are exposed to sub-MICs of the drug, not only are their physiological functions compromised, but gene virulence and antibiotic resistance are not fully expressed.

Original languageEnglish
Pages (from-to)186-194
Number of pages9
JournalJournal of Chemotherapy
Volume20
Issue number2
Publication statusPublished - Apr 2008

Keywords

  • Bactericidal activity
  • Conjugation
  • ETEC
  • Plasmid elimination
  • Rifaximin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations'. Together they form a unique fingerprint.

  • Cite this

    Debbia, E. A., Maioli, E., Roveta, S., & Marchese, A. (2008). Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. Journal of Chemotherapy, 20(2), 186-194.